

## Norliqva® (amlodipine) - New drug approval

- On February 24, 2022, the FDA approved CMP Pharma's Norligva (amlodipine) oral solution, for:
  - Treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older
  - Symptomatic treatment of chronic stable angina
  - Treatment of confirmed or suspected vasospastic angina
  - Patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction < 40%, to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.
- Amlodipine is also available as a tablet (<u>Norvasc<sup>®</sup></u>; generics available) and as an oral suspension (<u>Katerzia<sup>®</sup></u>).
- Warnings and precautions for Norliqva include hypotension, increased angina or myocardial infarction, and patients with hepatic failure.
- The most common adverse reactions with amlodipine use were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose related but reported with an incidence > 1.0% are fatigue and nausea.
- In adults, the usual initial antihypertensive dose of Norliqva is 5 mg orally once daily, and the maximum dose is 10 mg orally once daily. The recommended dose for chronic stable or vasospastic angina is 5 mg to 10 mg orally once daily and most patients will require 10 mg orally once daily for adequate effect. The recommended dose range for patients with coronary artery disease is 5 mg to 10 mg orally once daily and in clinical studies, the majority of patients required 10 mg.
- The effective antihypertensive oral dose in pediatric patients ages 6 years of age and older is 2.5 mg to 5 mg orally once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients.
- CMP Pharma's launch plans for Norliqva are pending. Norliqva will be available as a 1 mg/mL oral solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.